197 related articles for article (PubMed ID: 23028750)
1. Novel multiple markers to distinguish melanoma from dysplastic nevi.
Zhang G; Li G
PLoS One; 2012; 7(9):e45037. PubMed ID: 23028750
[TBL] [Abstract][Full Text] [Related]
2. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Kiszner G; Wichmann B; Nemeth IB; Varga E; Meggyeshazi N; Teleki I; Balla P; Maros ME; Penksza K; Krenacs T
Virchows Arch; 2014 May; 464(5):603-12. PubMed ID: 24682564
[TBL] [Abstract][Full Text] [Related]
4. α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Abbas M; Ploch EM; Wehling J; Schipper E; Janciauskiene S; Kreipe HH; Jonigk D
Tumour Biol; 2014 Dec; 35(12):12015-20. PubMed ID: 25149154
[TBL] [Abstract][Full Text] [Related]
5. Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count.
Dyduch G; Tyrak KE; Glajcar A; Szpor J; Ulatowska-Białas M; Okoń K
Biomed Res Int; 2017; 2017():6803756. PubMed ID: 28331853
[No Abstract] [Full Text] [Related]
6. A multi-marker assay to distinguish malignant melanomas from benign nevi.
Kashani-Sabet M; Rangel J; Torabian S; Nosrati M; Simko J; Jablons DM; Moore DH; Haqq C; Miller JR; Sagebiel RW
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6268-72. PubMed ID: 19332774
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
8. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
9. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
10. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
Lebe B; Pabuççuoğlu U; Ozer E
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
[TBL] [Abstract][Full Text] [Related]
11. Dysplastic nevi.
Farber MJ; Heilman ER; Friedman RJ
Dermatol Clin; 2012 Jul; 30(3):389-404. PubMed ID: 22800547
[TBL] [Abstract][Full Text] [Related]
12. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
[TBL] [Abstract][Full Text] [Related]
14. microRNA in situ hybridization for miR-211 detection as an ancillary test in melanoma diagnosis.
Babapoor S; Horwich M; Wu R; Levinson S; Gandhi M; Makkar H; Kristjansson A; Chang M; Dadras SS
Mod Pathol; 2016 May; 29(5):461-75. PubMed ID: 26916074
[TBL] [Abstract][Full Text] [Related]
15. Dysplastic nevi.
Clarke LE
Clin Lab Med; 2011 Jun; 31(2):255-65. PubMed ID: 21549239
[TBL] [Abstract][Full Text] [Related]
16. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
18. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
Schubert C; Parwaresch R; Rudolph P
Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
[TBL] [Abstract][Full Text] [Related]
19. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
Decarlo K; Yang S; Emley A; Wajapeyee N; Green M; Mahalingam M
Hum Pathol; 2010 Jun; 41(6):886-94. PubMed ID: 20233623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]